(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
| Title | Journal |
|---|---|
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. | The New England journal of medicine 20151126 |
| Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. | Clinical pharmacokinetics 20150701 |
| Empagliflozin for the treatment of type 2 diabetes. | Expert opinion on pharmacotherapy 20141101 |
| Empagliflozin (Jardiance) for diabetes. | The Medical letter on drugs and therapeutics 20141013 |
| Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. | Diabetes, obesity & metabolism 20141001 |
| Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. | Diabetes care 20140601 |
| Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. | Expert opinion on investigational drugs 20140601 |
| Empagliflozin for the treatment of Type 2 diabetes. | Expert review of clinical pharmacology 20140501 |
| Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. | Drugs in context 20140101 |
| Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. | International journal of toxicology 20140101 |
| Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. | Advances in therapy 20121001 |
| Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. | Diabetes, obesity & metabolism 20120701 |
| A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. | Annals of medicine 20120601 |
| [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors]. | Orvosi hetilap 20120506 |
| Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. | Diabetes, obesity & metabolism 20120101 |
| Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. | Diabetes, obesity & metabolism 20120101 |
| Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. | The Journal of clinical endocrinology and metabolism 20100101 |
| From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. | Current medical research and opinion 20090301 |
| Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080901 |